Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double Crossover, Open-Label, Active-Controlled Proof-of-Concept Study of CNSA-001 in Phenylketonuria Patients

Trial Profile

A Phase 2, Randomized, Double Crossover, Open-Label, Active-Controlled Proof-of-Concept Study of CNSA-001 in Phenylketonuria Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs CNSA-001 (Primary) ; Sapropterin
  • Indications Phenylketonuria
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Censa Pharmaceuticals Australia
  • Most Recent Events

    • 01 Nov 2018 According to a Retrophin media release, patient dosing has been commenced in the study. Top-line data expected in first half 2019.
    • 24 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 26 Jul 2018 According to a Retrophin media release, the trial is expected to commence patient dosing in the coming weeks and top-line data are expected in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top